Administracin: Dosis por aplicacin: 150 mcg Frecuencia: 2 veces al da (maana y noche, preferiblemente en ayunas)
2020 Jun 30;8(1):13
[ CrossRef ] [ Google scholar ] [ PubMed ] Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, et al
Medical Weight Loss in Nashville, TN | Bariatric Supervised Weight Loss Injections Are you struggling with weight loss and looking for a medically supervised solution
Instruct patients to contact their physician if cholelithiasis or cholecystitis is suspected for appropriate clinical follow-up [see Warnings and Precautions (5.8)]
Limitations of Use Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
.png)
